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AbstrAct
The cluster randomised trial (CRT) is commonly used in 
healthcare research. It is the gold-standard study design 
for evaluating healthcare policy interventions. A key 
characteristic of this design is that as more participants 
are included, in a fixed number of clusters, the increase 
in achievable power will level off. CRTs with cluster 
sizes that exceed the point of levelling-off will have 
excessive numbers of participants, even if they do not 
achieve nominal levels of power. Excessively large cluster 
sizes may have ethical implications due to exposing 
trial participants unnecessarily to the burdens of both 
participating in the trial and the potential risks of harm 
associated with the intervention. We explore these issues 
through the use of two case studies. Where data are 
routinely collected, available at minimum cost and the 
intervention poses low risk, the ethical implications of 
excessively large cluster sizes are likely to be low (case 
study 1). However, to maximise the social benefit of 
the study, identification of excessive cluster sizes can 
allow for prespecified and fully powered secondary 
analyses. In the second case study, while there is no 
burden through trial participation (because the outcome 
data are routinely collected and non-identifiable), the 
intervention might be considered to pose some indirect 
risk to patients and risks to the healthcare workers. 
In this case study it is therefore important that the 
inclusion of excessively large cluster sizes is justifiable 
on other grounds (perhaps to show sustainability). In 
any randomised controlled trial, including evaluations of 
health policy interventions, it is important to minimise the 
burdens and risks to participants. Funders, researchers 
and research ethics committees should be aware of the 
ethical issues of excessively large cluster sizes in cluster 
trials.
the cluster rAndomised 
controlled triAl
The cluster randomised trial (CRT) is 
increasingly being used to evaluate inter-
ventions that cannot be evaluated using 
the conventional individually randomised 
trial. CRTs proceed by randomising clus-
ters of individuals to intervention or 
control conditions, with typical examples 
of clusters being hospitals, general prac-
tices and schools. These designs are used 
across a breadth of contexts, and evaluate 
a diverse range of interventions from 
health services or policy interventions1 to 
drug therapies.2–4 
As with all research involving human 
participants, CRTs should be conducted 
in accord with appropriate scientific 
and ethical principles. One scientific and 
ethical standard is that an appropriate 
power calculation should be carried out, 
to ensure the study has enough partic-
ipants to detect the target difference. 
However, it has been argued that trials 
that accrue needlessly large numbers of 
participants may violate ethical princi-
ples by exposing excessive numbers of 
participants to the burdens and risks of 
study participation.5 6 We use the term 
‘excessively large cluster sizes’ to notion-
ally represent cluster sizes in which some 
observations make a negligible contribu-
tion to the study’s primary aims.
In this paper, we argue that this issue 
is of particular importance in a CRT. 
This is because, uniquely to a CRT, some 
participants in a cluster may contribute 
little information to the study.7–10 The 
statistical implications of these excessive 
cluster sizes have been outlined else-
where, including how simple changes to 
the trial design can deliver close to the 
desired statistical power without compro-
mising the value of the trial.11 However, 
the ethical implications of excessive 
cluster sizes may vary according to the 
type of CRT, but have not yet been fully 
articulated.
When interventions are low risk 
and study participation poses little or 
no burden, for example, when data 
are routinely collected and non-iden-
tifiable,12 13 there may be no ethical 
implications or implications may be 
inconsequential. However, excessive 
cluster sizes will have ethical implications 
when the intervention poses some risk 
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to participants or there is some burden posed with 
trial participation. The objective of this paper is to 
raise awareness of these issues to prompt funders, 
researchers and ethics committees to ensure maximum 
social and scientific value of cluster trials, while at the 
same time minimise the number of participants who are 
exposed to the burden and risks of trial participation.
We introduce two case studies with large cluster 
sizes. These case studies raise a number of important 
issues, many of which are common to large prag-
matic CRTs. We discuss each of these case studies in 
turn, considering for each the ethical implications 
of including excessive cluster sizes. We consider in 
particular the risks and burdens for participants, and 
whether these can be justified when it is known that 
some participants provide little information to the 
primary outcome.
diminishing returns in crts
It has been known for some time that the power in 
a CRT begins to reach a plateau as the cluster size is 
increased,7–10 and a set of practical recommendations 
for designing cluster trials so that they make efficient 
use of their data has recently been published.11 At 
the core of these recommendations is the fact that, in 
cluster trials, increasing cluster sizes, even by a vast 
amount, may result in negligible gains in power. This 
levelling-off is dependent on several design parameters, 
including the intracluster correlation coefficient (ICC) 
(which measures the extent to which observations 
within a cluster are correlated) as well as the target 
effect size. Target effect sizes should be clearly justified 
and should ideally be based on the minimally impor-
tant difference.14 15
How the increase in power begins to level off as the 
cluster sizes increase is illustrated in figure 1 using a 
series of power curves (for full details of calculations, 
see Hemming et al11). For example, when the ICC is 
0.01 the power to detect a standardised effect size 
of 0.25 with 12 clusters per arm plateaus when the 
cluster size is about 100. This means that, when the 
standardised effect size of 0.25 is truly the minimally 
important clinical difference, participants above a 
threshold of 100 add little value to the analysis of the 
primary outcome of the study.
An additional complication is that while partici-
pants’ contribution to the power may be negligible, 
participants might still make a valuable contribution 
to the study should the minimal important effect be 
smaller than the target effect assumed in the sample 
size calculation. For example, in figure 1, when the 
ICC is 0.01 the precision (ie, 1/variance of the treat-
ment effect) continues to increase up to cluster sizes 
of about 1000. This means that while cluster sizes of 
about 100 would be sufficient to detect an effect size 
of 0.25, the CI width around smaller effect sizes will 
Figure 1 Illustration of diminishing returns in precision as cluster size increases, for typical intracluster correlation coefficient (ICC) values. Curves show 
increases in power (blue line) and precision (red line) as cluster size increases. All power curves correspond to a cluster randomised trial with 12 clusters per 
arm, designed to detect a standardised effect size of 0.25. At a significance level of 5%, 338 individuals per arm are required to yield 90% power under 
individual randomisation. Precision curves are independent of effect size (assumed to be continuous outcome). Dashed lines represent required sample size 
per arm under individual randomisation.
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continue to decrease up to cluster sizes of about 1000. 
This may be valuable if the actual effect size is smaller 
than the target difference but still clinically important.
It is important to bear in mind that these calcula-
tions depend on estimated parameters such as the ICC. 
Ideally, power and precision curves should take into 
account the uncertainty in these estimates and should 
be considered across a range of scenarios, as with any 
power calculation. All our calculations have assumed 
equal cluster sizes and large sample theory. Specific 
recommendations have been provided for inflating 
the sample size to accommodate varying cluster sizes 
using the coefficient of cluster size variation, and this 
equates to increasing the number of clusters per arm 
by 2 or 3.16 17 There are other CRTs that are statisti-
cally more efficient, that is, deliver the same power 
for a substantially reduced total sample size. These 
include the cluster randomised cross-over trial (only 
a feasible design choice when the intervention can be 
withdrawn) and some trials with premeasurements in 
a baseline period.18
ethicAl issues in studies with excessively 
lArge cluster size
A cornerstone of the ethics of medical research is 
that the risks to study participants must be reasonable 
when considering the potential benefits to them and 
to society. Researchers and research ethics committees 
must (1) minimise risks to participants consistent with 
sound scientific design and (2) ensure that knowledge 
benefits outweigh risks.19 20 Studies that accrue need-
lessly large numbers of participants may violate one or 
both requirements by exposing some participants to 
research burdens and risks needlessly.
Risks to research participants may include exposure 
to a treatment or service that is inferior (eg, when a trial 
continues beyond the point at which the inferiority 
of an intervention could have been detected, thereby 
needlessly exposing intervention participants to an 
inferior treatment); being denied access in a timely 
manner to treatment (eg, when trial continues beyond 
the point at which the superiority of an intervention 
could have been detected, thereby needlessly exposing 
control participants to an inferior treatment); or expo-
sure to the burdens associated with data collection or 
other non-therapeutic study procedures.
Burdens and risks to society also include being 
denied access to treatments or services when a trial 
continues beyond the point at which the superiority 
of an intervention could have been detected. Other 
burdens and risks to society include a financial cost 
and delay in answering the study question.
Appropriate identification of research partici-
pants is essential to conducting a proper analysis of 
benefits and harms: only those individuals who are 
research participants logically fall under the remit of 
the research ethics committee. Therefore, identifi-
cation of research participants can help determine if 
excessive cluster sizes are consequential. The Ottawa 
Statement provides explicit criteria for identification 
of research participants in a CRT20: in brief, individ-
uals are research participants when they are targeted 
by a study intervention and/or have their identifiable 
private information collected for research.
implications in lower risk or low burden settings
Many CRTs evaluate interventions such as health 
promotion or knowledge translation interventions, 
which pose little burden or risk to trial partici-
pants. Burdens are minimal because outcomes might 
be obtained in de-identified form using routinely 
collected data sources. In this situation, the data might 
be considered available for ‘free’. That is, once data 
linkage has been established, the number of observa-
tions included per cluster, whether from 500 or 5000 
participants, is largely immaterial. If the intervention is 
low risk and routinely collected outcome data are avail-
able, there are few ethical implications of large cluster 
sizes. Some CRTs evaluate interventions targeted at 
health professionals but assess outcomes on patients. 
In such trials if patients are not interacted with for 
elicitation of outcome data they will not be research 
participants. However, healthcare professionals might 
still be research participants, although are frequently 
not identified as such.21
In case study 1, the ASCEND trial,22 cluster sizes 
were set by the average number of invitations that 
each screening region posted each day. Figure 2 shows 
that a similar level of power could have been achieved 
with a much smaller cluster size (while retaining 50 
clusters) for the anticipated ICC of 0.0002 (see online 
supplementary appendix 1 for more details on the 
calculations). However, the figure also demonstrates 
that all observations would make a material contri-
bution to the precision of the treatment effect, if the 
effects of the intervention were smaller than that 
allowed for in the power calculation. Small abso-
lute changes might be materially important to the 
screening programme, but if so should be specified in 
advance.14
If it is the case that smaller effects were not 
important, not all observations would have made 
a material contribution to the prespecified primary 
outcome analysis. Smaller cluster sizes might then 
have been achievable, for example, by composing half 
region-days instead of full region-days and running 
the trial for 10 half days instead of 10 full days (and 
so retaining 50 clusters). However, logistics may have 
meant that it was not practically possible to change 
the leaflet type midway through the day, or this may 
have added cost implications. In this situation, an 
acknowledgement and awareness of the negligible 
contribution of a substantial proportion of the data 
could have allowed important secondary outcomes (or 
safety outcomes, in other trials where applicable) to be 
included as fully powered analyses.
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In this trial, citizens were research participants: the 
study intervention is a leaflet that seeks to increase 
their participation in cancer screening. Researchers 
should consider carefully the implications of exces-
sive cluster sizes on the study research participants. 
However, because the intervention likely poses negli-
gible risks or burdens to participants and may even be 
beneficial for low socioeconomic groups, and because 
larger cluster sizes do not increase the costs or time 
required for the trial, the excessive cluster sizes are 
likely to be inconsequential. Nonetheless, the bene-
fits to society may have been increased if the trial had 
made more efficient use of the data (eg, prespecified 
important secondary analyses).
implications in higher risk or higher burden settings
Trial participation can pose some burden or risk for 
participants, particularly when evaluating higher risk 
interventions. A small but not insignificant minority 
of CRTs evaluate higher risk interventions, including 
medicinal products such as vaccines,23 and what consti-
tutes low risk may be contentious, as the second case 
study illustrates.24–26 Moreover, even trials of low-risk 
interventions can pose some burden to participants, 
for example, the burden of questionnaire comple-
tion and other procedures to elicit outcomes (such as 
blood draws).19 In these studies, individual patients or 
healthcare professionals are more likely to be human 
research participants since interventions might either 
be directly or indirectly targeted at them, and they may 
also be interacted with for elicitation of outcome data.
In case study 2, the Flexibility in Duty Hour Require-
ments for Surgical Trainees (FIRST)  trial,27 cluster sizes 
were set by the average number of patients admitted to 
each hospital over the duration of 1 year. Figure 3 demon-
strates that for this design, cluster sizes above a threshold 
of about 1000 make minimal contribution to power (as 
per the effect size specified and under a non-inferiority 
Case study 1 The ASCEND trial: evaluation of a 
low-risk intervention with excessively large sizes
Background
A cluster randomised trial published in The Lancet in 2016 
evaluated an intervention to increase colorectal screening 
uptake and reduce the socioeconomic differences 
between uptake rates.22 The intervention consisted of 
a leaflet designed specifically to communicate complex 
information to readers with low literacy (trial 1 in paper). 
The trial was powered for a primary analysis of testing 
whether the effect of the intervention differed across 
different socioeconomic status groups (ie, an interaction). 
This trial lasted 10 consecutive working days and was 
run across five UK screening regions. The outcome data 
were routinely collected. The unit of randomisation was 
a region-day (the clusters); thus, the trial included 50 
clusters: 25 randomised to receive the intervention and 
25 randomised to current practice. The cluster size was 
fixed by the number of invitations sent out (per region) in 
any given day.
Power calculation
The trial was designed with 90% power and 5% 
significance and required 13 500 observations per 
arm under individual randomisation. This was inflated 
to allow for clustering, assuming an intracluster 
correlation coefficient of 0.0002. The trial protocol states 
that the sample size was further inflated to increase 
generalisability and reduce internal validity issues 
associated with trials with a small number of clusters. The 
final number of clusters was 5 regions over 10 days (ie, 
50 clusters).
Number of participants included
The trial enrolled 50 clusters and a total of 163 255 
people contributed to the primary outcome, equating to 
an average cluster size of 3265.
Figure 2 Power and precision curves for ASCEND trial. Curves show increases in power (blue line) and precision (red line) as cluster size increases, 
assuming a cluster randomised trial with 25 clusters per arm, designed to detect a standardised effect size of 0.04, at a significance level of 5% (which 
requires a sample size of 13 500 per arm under individual randomisation), and assuming an intracluster correlation coefficient of 0.0002. Vertical solid line 
represents cluster size in the study (3000). Full details of calculations are provided in online supplementary appendix 1.
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design) or precision. Reducing the cluster sizes from 
about 1200 to 600 would have reduced power only 
marginally from about 85% to 79% (see online supple-
mentary appendix 1 for full details of calculations).
The obvious way to reduce the cluster size in this 
study is to reduce the duration of the trial (as outcomes 
were obtained anonymously from routinely collected 
sources, selecting a random sample of outcomes would 
not be meaningful). For example, conducting the trial 
over half a year instead of a full year would have 
reduced the cluster sizes from about 1200 to 600. Such 
a change would have reduced power only marginally 
from about 85% to 79% (figure 3). In so doing the 
finding that the change to flexible working hour poli-
cies was no worse for patient outcomes or resident 
well-being might possibly have been reported after 
only 6 months instead of 1 year, allowing this non-in-
ferior intervention to be rolled out to other hospitals 
sooner.
There may have been practical or scientific reasons 
for implementing the new resident duty hour poli-
cies over a 1-year period. For example, it may have 
been difficult to change resident duty hour policies 
halfway through an academic year. Yet, as in case 
study 1, an acknowledgement and awareness of the 
negligible contribution of a substantial proportion 
of the data could have allowed important secondary 
or safety outcomes to be included as fully powered 
important secondary analyses. These might include 
demonstrating sustainability of the effect over a 
prolonged period of time. But, again, such a justi-
fication needs to be prespecified, and the analysis 
Case study 2 The FIRST trial: evaluation of a higher 
risk intervention with excessively large cluster sizes
Background
The FIRST trial was a cluster randomised trial, published in 
The New England Journal of Medicine in 2016, evaluating 
the effect of flexible maximum shift length policies on 
patient outcomes (serious complication or death) and 
trainee doctors’ well-being.24 The cluster randomised 
trial enrolled 117 general surgery residency programmes 
(the clusters) in the USA and ran from 1 July 2014 to 30 
June 2015. Each residency programme was randomly 
assigned to either the standard working hour policy or 
a more flexible policy with waived rules on shift lengths. 
Data on primary patient outcomes were ascertained from 
routinely collected data.
Power calculation
The trial had a non-inferiority design, powered at 80% 
on a composite of serious patient complications, which 
had an estimated baseline rate of 9.94%; with an 
absolute non-inferiority margin of 1.25%, equating to 
an upper bound of 11.19%; and an adjusted alpha value 
of 0.04 to allow for an interim analysis. To replicate 
this non-inferiority calculation, we double the alpha 
value (ie, 0.04×2) and retain a two-sided test. This 
requires a sample size of 7750 per arm under individual 
randomisation. The intracluster correlation coefficient was 
estimated to be 0.004.
Number of participants included
The trial enrolled 117 clusters and a total of 138 691 
patients contributed to the primary outcome, equating to 
an average cluster size of 1185 patients.
Figure 3 Power and precision curves for the FIRST trial. Curves show increases in power (blue line) and precision (red line) as cluster size increases, 
assuming a cluster randomised trial with 45 clusters per arm, designed to detect a difference from 9.94% to 11.19%, at a significance level of 8%, and 
assuming an intracluster correlation coefficient of 0.004. Vertical solid line represents cluster size in the study (1185). Full details of calculations are 
provided in online supplementary appendix 1.
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formulated in such a way so as to demonstrate these 
effects.
In this trial, patients were not research participants 
since the study interventions were neither targeted at 
them; there were no additional burdens due to data 
collection; and all data that were used were non-identi-
fiable.18 However, trainee doctors are research partici-
pants, being the direct target of the intervention. The 
implications of excessive cluster sizes on the trainee 
doctors should therefore be carefully considered (AR 
Horn et al, under review). The trial received criticism 
from some patient and doctor groups, citing increased 
risks associated with the intervention.24–26 Shortening 
the duration of the trial may have ameliorated some 
of the concerns of those criticising the trial, again 
increasing the social benefit of the trial.
This second case study is therefore an example where 
researchers (including those on funding and ethical 
review boards) could have benefited from the knowl-
edge that a substantial proportion of the data made 
very minimal contribution to the primary analysis. 
While viewed by some as a low-risk intervention, there 
was much debate over the risks of the trial. The trial 
should be designed to answer the question by exposing 
the minimum number of participants as possible to 
these perceived/debated trial risks. While there may 
have been reasons as to why the trial was needed to 
run for 1 year (this was the cause of the large cluster 
sizes), these were not articulated, and because this fact 
was not identified by the researchers the ‘extra’ data 
were not put to good use (ie, a prespecified and fully 
powered secondary analysis).
conclusions
Researchers, funders and research ethics committees 
need to carefully consider whether all participants in 
CRTs will contribute information to the study (box 1). 
The point beyond which further recruitment or inclu-
sion of participants makes a trivial contribution to the 
treatment effect estimate can most easily be ascertained 
by the use of power or precision curves.11 This issue 
is particularly important when the trial is evaluating 
an intervention that poses substantial burdens or risks 
to the participant, or when large cluster sizes increase 
social or financial burden.
For CRTs where individuals are not considered 
human research participants or CRTs evaluating rela-
tively innocuous interventions that pose little or no risk 
to participants, excessive cluster sizes are unlikely to 
be ethically problematic (case study 1).22 In these situa-
tions, when observations are ‘free’, researchers should 
consider powering the trial for important subgroup 
differences or safety outcomes so that data do not 
go to waste.28 When there are trial or data collection 
costs, a more efficient trial design may improve the 
efficiency of the trial and its social value.
For CRTs evaluating interventions that are associ-
ated with some burden or risk to participants, or costs 
to society, any excessive cluster sizes must be justified 
(case study 2).27 Possible justifications include a desire 
to demonstrate sustainability, to estimate learning 
effects or to allow time for the intervention to become 
embedded in practice. Occasionally a net benefit 
might be provided to those participating in the trial, 
for example access to a known beneficial treatment or 
service that is not available outside of the study in a 
lower income or middle-income country, for example; 
or in vaccination studies in which there are both direct 
and indirect effects of the intervention. Otherwise 
excessive cluster sizes potentially expose individuals 
to needless risks while offering little or no additional 
social value.
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Box 1 Recommendations to avoid undue exposure 
to burden or risks associated with participation in a 
cluster trial
 ► Due consideration must be given to the balance 
between recruiting large cluster sizes in pursuit of 
desired but notional levels of power and the burdens 
and risks to the individual participants. Proper 
identification of human research participants in cluster 
randomised trials can aid such considerations.
 ► Ethically designed trials might reduce the total 
number of participants being exposed to the burdens 
associated with trial participation and the possible 
risks associated with the intervention being evaluated. 
This might be achieved by recruiting a smaller number 
of participants from clusters or running trials for a 
shorter duration.
 ► When data are routinely collected and the intervention 
has minimal risk, then large cluster sizes may be 
acceptable as there will be minimal if any burden on 
participants. Furthermore, these large cluster sizes 
if prespecified may lead to improvement in power 
for secondary analyses or allow analyses showing 
sustainability of effect.
 ► When the intervention carries some risk or there 
are participant burdens related to data collection, 
then trials might be designed with slightly less than 
nominal levels of power to avoid excessive numbers 
of participants making a minimal or negligible 
contribution to the trials’ primary objective.
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